Organic Active Ingredients TRIZ Cases

Phenylene diamine derivatives strengthen tight junction signaling and host-defense peptides to block pathogen translocation without dysbiosis.

Controlled backbone stereochemistry and sugar modifications improve ds oligonucleotide stability, Ago2 activity, and cellular delivery.

Cell-specific neuronal promoters and retrograde AAV targeting improve D1-MSN precision in Parkinson's circuits to restore motor function.

8-azaquinazoline compounds improve SOS1-KRAS inhibition while reducing efflux and enabling brain penetration for metastatic tumor treatment.

Adjusted capivasertib and venetoclax dosing cycles maintain anti-cancer efficacy in B-cell malignancies while reducing body weight loss.

Targeted deuterium substitution at the 3-position slows racemization, preserving stereoisomeric purity and therapeutic activity.

6,6-heterocyclic scaffolds tune DYRK and CLK inhibition to broaden disease coverage while managing selectivity and off-target effects.

Bicyclic C3 glutarimide degrons improve cereblon binding and enable more selective degradation of disease-associated proteins.

Crosslinked polymer DHA analog formulations sustain retinal and inner ear drug levels, overcoming barrier limits without repeated injections.

Allele-specific antisense oligonucleotides selectively silence pathogenic FUS variants while preserving normal FUS expression in ALS and FTD treatment.

Stimulus-responsive binary copolymer hydrogels occlude tear ducts with better fit, lower extrusion and migration, and easier removal.

A heterocyclic compound and neurospheroid model address the lack of reliable evaluation for reducing α-synuclein aggregates in the brain.

LSD1 inhibition during CAR T or NK cell preparation increases naive cells, reduces exhaustion, and improves anti-tumor response.

UV-driven cascade synthesis converts aromatic precursors into complex anticancer polyheterocycles with higher selectivity under mild conditions.

Early PDE5 inhibitor dosing after low-level blasts helps preserve brain vascular integrity, mitochondrial function, and long-term neurological health.

A substituted gamma-carboline compound targets 5-HT2A and SERT pathways to treat CNS disorders while reducing dopamine-related side effects.

PPI-TAC chroman compounds degrade ERα to improve bioavailability, reduce resistance, and strengthen treatment of ER-mediated breast cancer.

PROTAC compounds target residual immunoglobulin light chains for degradation or stabilization to reduce organ toxicity in light chain amyloidosis.

Cationic amphiphilic compounds replace ionizable lipids in LNPs to improve nucleic acid endosomal escape while reducing toxicity.

Blocking S100A9-ALDH1A1-retinoic acid signaling with pan-RAR antagonists helps curb osimertinib-refractory brain relapse in EGFR-mutant lung cancer.

Selective glycolipid activators boost iNKT cytokine release through CD1d engagement to reduce senescent cells linked to chronic disease.

High-concentration non-cross-linked hyaluronan relieves dry eye, skin, and wound pain by combining elasticity with TRPV1 interaction.

Anti-PD-L1 antibodies enhance T-cell function and cell-mediated immunity while addressing exhaustion in tumors and chronic infections.

A selective NOX2 inhibitor compound expands treatment options by blocking ROS-driven pathways in inflammatory, fibrotic, and neurodegenerative disease.

MC16 promotes mitochondrial biogenesis in injured renal tissue, improving kidney function and lowering injury markers in AKI.

Particle size control and granulation turn AN0025 into tablets with more uniform dissolution and lower in vivo exposure variability.

Targeting SCD1 enzyme activity reduces liver lipid accumulation and improves liver function in NAFLD and NASH without relying on transplant.

Tramadol enables a preservative-free ophthalmic composition that inhibits microbial growth while avoiding corneal epithelial disorders.

Controlled low-temperature crystallization creates a stable TETA tetrahydrochloride form that resists humidity and supports oral Wilson's disease treatment.

A 6,6-heterocyclic scaffold targets DYRK and CLK kinases to modulate WNT signaling across neurodegenerative, autoimmune, and cancer therapy.

Xanthine compounds are tuned to inhibit or activate TRPC4/5 channels with higher selectivity and efficacy for TRPC-related diseases.

A cationic lipid composition balances transfection efficiency and toxicity by enabling extrahepatic, spleen-directed nucleic acid delivery.

Pyrazolopyridine derivatives inhibit USP1 to expand treatment options for DNA repair and tumor diseases linked to USP1 activity.

A ruthenium-based visible light system cross-links PEG hydrogels without UV lamps, reducing cell toxicity while preserving gel formation control.

Targeted budesonide release in the distal ileum treats IgA nephropathy while lowering pathogenic IgA and limiting systemic side effects.

Steady transdermal dronabinol delivery avoids oral variability and first-pass metabolism while improving dosing convenience and serum consistency.

Pyrazolopyrimidine SRC kinase inhibitors improve selectivity over ABL to reduce cardiotoxicity, immunosuppression, and pro-oncogenic effects.

Combining CD4 lymphocyte depletion with checkpoint inhibitors reduces Treg suppression and strengthens immune stimulation for cancer and infectious disease treatment.

C3-disubstituted 19-nor steroids improve solubility and metabolic stability, enabling safer oral treatment of CNS disorders.

Small molecules bind ATXN3 pre-mRNA to shift splicing, lower full-length ATXN3, and help delay Spinocerebellar Ataxia 3 progression.

A heparin-loaded depot and foam filter reduce inflammation, coagulation, and cannula encapsulation to extend insulin infusion at one site.

Combining chidamide and celecoxib modulates the tumor microenvironment to improve immune response, overcome resistance, and boost anti-cancer activity.

Biodegradable tail groups in ionizable cationic lipids improve nucleic acid delivery while reducing toxicity and metabolic clearance.

Localized 6,7-epoxytiglienone treatment triggers immune-mediated regression of distant tumours, addressing the rarity of systemic abscopal effects.

Novel urea compounds inhibit NAMPT through modular structural variation, addressing inadequate cancer treatment with a targeted therapeutic approach.

A benidipine tablet uses polyvinyl alcohol and low disintegrant loading to improve dissolution, stability, and content uniformity.

Antioxidant additives keep dexamethasone cyclodextrin eye drops pH-stable during storage, limiting oxidation and degradation.

Rho kinase inhibition with fasudil reduces cortical dementia wandering, helps prevent elopement, and avoids chemical restraints.

Selective receptor targeting with roluperidone helps prevent schizophrenia relapse while avoiding dopamine-related sedation and Parkinsonism.

Cell-penetrating antibodies non-covalently bind nucleic acids to improve cellular uptake while avoiding viral vector complexity and immunological risks.

Porous microcrystalline cellulose and tuned excipient ratios help high-load AG10 tablets resist erosion and retain dissolution consistency during storage.

ACEi and ARB therapy can trigger aldosterone breakthrough, while spironolactone may cause hyperkalemia; selective CYP11B2 inhibition offers a targeted alternative.

Substituted N-heteroaryl compounds activate Kv3.1 and Kv3.2 channels to restore PV interneuron firing while limiting sedative side effects.

NAPs and vasoconstrictors increase cellular uptake of botulinum neurotoxin, extending efficacy and effect duration while reducing dosing frequency.

Furazidin targets Gardnerella and Atopobium while minimally affecting Lactobacillus flora, addressing recurrence and inflammation.

See how locally delivered TREMs modulate protein translation and induce immune responses in proliferative tumors.

Coated Tapentadol particles combine rapid onset with prolonged release while limiting alcohol-induced dose dumping.

Limited chemotherapy response is addressed with CDK4/6 inhibition, which restrains tumor proliferation in dedifferentiated liposarcoma.

GZMK-positive effector memory T-cell profiles in peripheral blood support myeloma monitoring and treatment decisions without repeated painful biopsies.

Convection-enhanced delivery uses functionalized nanoparticles to improve brain distribution and target glioma stem cells beyond diffusion limits.

Voxelotor preconditioning replaces red blood cell transfusions before plerixafor, supporting HSPC mobilization while reducing vaso-occlusive and alloimmune risks.

Amorphous solid dispersions address inadequate CCR6 inhibition by improving picolinamide solubility and bioavailability.

A core-sheath EVA ring separates estrogenic and progestational steroids to control independent release without complex assembly.

A TLR9 agonist and VISTA inhibitor reprogram tumor myeloid cells, helping recruit systemic immunity into non-inflamed tumors.

Specific Lactilactobacillus strains colonize the gut, inhibit pathogens, and support aquaculture health without relying on antibiotics.

Separate zinc or silver and chlorite fluids form a charged irrigant that raises wound-site redox potential and inhibits bacterial metabolism.

Water-based, hydrophilic coatings deliver anti-inflammatory and antiproliferative drugs rapidly without oil-dependent lipolysis.

Covalently tethering a non-targeting accessory oligonucleotide to dsRNA supports tissue access, bioavailability, and cellular uptake.

A sugar-sphere core and plasticized ethyl cellulose layer control huperzine release to reduce nausea and vomiting.

By inhibiting XIAP, cIAP1, and cIAP2, these bicyclic compounds promote apoptosis and increase cancer-cell sensitivity to chemotherapy.

Furosemide addresses coronavirus-related cytokine storm by reducing pro-inflammatory cytokines and promoting anti-inflammatory markers.

Synthetic heparan sulfate biopolymers target ischemic penumbra damage to reduce neuronal death, demyelination, and hemorrhagic transformation.

Paclitaxel-resistant cancer cells show cytostatic sensitivity to trimethoxystyryl derivatives, offering an alternative treatment approach.

Live probiotics can be difficult to stabilize industrially; this case uses inactivated Pediococcus acidilactici components for obesity management.

These compounds inhibit DGKα and DGKζ to enhance T cell activation while addressing selectivity over other kinases and drugability needs.

A heated aqueous solution releases elemental iodine as controlled vapor, balancing respiratory pathogen killing with mucosal toxicity.

Postprandial hyperglycemia can challenge endothelin-1 inhibition; this case uses continuous isomaltulose intake to address it.

Extracellular vesicles carrying therapeutic agents help overcome blood-brain barrier obstruction and support CNS treatment.

Replacing sugar alcohols with glucose, maltose, and selected excipients supports Edoxaban tablet dissolution, bioavailability, and storage stability.

Cold plasma-generated RONS combined with a STAT3 inhibitor targets cancer cells and cancer stem cells while sparing healthy cells.

Non-selective PARP1/2 inhibition can cause anaemia and neutropenia; selective PARP1 compounds aim to preserve efficacy with less haematotoxicity.

Weak-base sodium salts convert ropinirole acid salts to the free base, supporting transdermal permeation without metal-salt growth.

Metabolic instability and toxicity limit AURKA therapies; imidazo[4,5-b]pyridine compounds modulate TPX2 binding for a wider therapeutic index.

Learn how fine PVA particles and crystalline cellulose increase tablet hardness while suppressing early drug release.

Existing treatments do not regenerate mammalian cochlear hair cells; CK1 inhibitors target WNT/β-catenin signaling to promote regeneration.

Poorly soluble opiranserin is formulated with sodium benzoate, trisodium citrate, or sodium salicylate for stable, small-volume intravenous dosing.

Alport syndrome therapies may control blood pressure without preventing renal disease or hearing loss; sparsentan targets both receptor pathways.

RET mutations G810R, G810S, and G801C can weaken ATP-site binding; anhydrous and solvated crystal forms support stable, potent inhibition.

A rapidly absorbed abiraterone precursor hydrolyzes to the active drug, increasing bioavailability and plasma concentration.

Structured variation of heterocyclic rings, substituents, and stereochemistry is used to activate TREM2 and improve microglial signaling.

An interface mediator stabilizes dispersed active-agent deposits in a biphasic adhesive layer, limiting coalescence and release fluctuation.

Specific small-molecule structures inhibit ERK1/2 activity to address dysregulated MAPK signaling across several cancers.

Tricyclic heterocyclic compounds target FGFR enzymes, particularly FGFR3, to address inadequate cancer treatment and resistance to conventional therapies.

Combining SGLT2 inhibition with PDE5 inhibitors or alprostadil targets diabetic ED while improving glycemic control.

An HPMCAS amorphous dispersion and swellable polymer layer sustain apremilast release for 24 hours and support once-daily dosing.

Noise, antibiotics, and aging can damage sensory hair cells; EGFR inhibitors act early to protect hearing before loss develops.

Mitochondrial malfunction raises ROS and lowers ATP; KB1541 upregulates 14-3-3 zeta/delta and ATP synthase to restore function in senescent cells.

These compounds target PKM2’s distinct allosteric features to address poor isoform selectivity while modulating cancer-cell proliferation.

Sequence-specific siRNA conjugates target ANGPTL3, addressing limited gene inhibition in dyslipidemia while improving biological stability.

A silicone rubber sheet separates uterine walls while sustained estrogen release supports basal-layer recovery and helps prevent re-adhesion.

Nicotinamide mononucleotide derivatives reduce arrhythmia frequency by modulating intracellular NADH levels.

Novel compounds inhibit PI3-kinase activity with selectivity towards PI3Kδ, addressing poor specificity of current inhibitors.

TUDCA resolves inflammation trade-offs during stem cell mobilization while preventing senescence to enhance vascular repair.

Engineered antibody-drug conjugate uses specific linker to maintain plasma stability while delivering cytotoxic payload to B7H3-expressing tumors.

Baricitinib inhibits JAK1 and JAK2 enzymes to preserve insulin secretion, addressing the trade-off between glucose control and beta-cell function.

Genetically modified microalgae produce pigment-free polysaccharides that prevent skin staining while retaining antioxidant properties.

3-indol pyridine derivatives overcome limited inhibitor affinity by optimizing molecular structures to block TDO2-mediated immunosuppression in tumors.

Low-temperature micronization prevents artemether degradation while enabling stable injection formulations with minimal toxicity.

A flavored composition combining resistant dextrin, corosolic acid, and chromium attenuates post-prandial glucose and lipid increases.

Engineered silk-elastin-like protein polymers deliver bioactive agents via protease-responsive cleavage sites.

Two polymer-active agent conjugate populations with distinct molecular weights deliver rapid onset and sustained pharmacological activity.

Triphosphate phosphoramidate salts resolve the trade-off between therapeutic efficacy and poor solubility in monophosphate prodrugs.

Bi-steric mTOR inhibitors induce tumor cell apoptosis and delay acquired resistance to RAS inhibitors.

Natural herbal compounds block androgen receptor activity, resolving resistance and side effects in prostate cancer treatment.

Modified nicotinamide mononucleotide derivatives overcome antiviral resistance and side effects while maintaining therapeutic efficacy.

A colon delivery article uses a secretion-inducing agent to stimulate intestinal fluid release for enhanced therapeutic absorption.

Combines a multi-kinase inhibitor with paclitaxel to enhance cancer treatment outcomes through synergistic interaction.

Assigning distinct physical states to each antiviral compound resolves the contradiction between dissolution rate and chemical stability.

Benzimidazole heteroatom-containing spiro compounds exhibit strong antiproliferative activity against liver, colon, and gastric cancer cells.

Cross-linking stabilizes polymer micelles against premature disintegration, preventing rapid drug diffusion and burst release.

Compounds targeting the Aldolase-TRAP interface inhibit glideosome function, addressing parasite resistance in malaria treatment.

Amphiphilic cellulosic polymers stabilize hydrophobic nanoparticle cores against aggregation during spray drying and redispersion, ensuring size consistency.

Novel benzothiazole compounds act as selective protease-activated receptor 4 antagonists to inhibit platelet aggregation.

Pairing HDAC6 selective inhibitors with BET blockers reduces dose-limiting toxicities while sustaining anti-tumor efficacy.

Biodegradable polyphosphazene conjugates resolve rapid small-molecule diffusion by chemically bonding drugs to a thermosensitive polymer network.

3-Hydroxyanthranilic acid levels serve as a biomarker for aneurysm detection while kynureninase inhibitors block pathological progression.

Topical albaconazole film treats resistant fungal infections without systemic side effects.

A bioactive releasing membrane delivers dexamethasone to modify local tissue responses around an implantable sensor.

A bilayer tablet separates atazanavir and cobicistat into distinct layers, preventing chemical degradation while simplifying patient dosing.

Formula I heterocyclic compounds disaggregate Tau aggregates and prevent their formation.

Dual JAK1 and TYK2 inhibition by bridged heterocyclyl-substituted pyrimidine compounds addresses incomplete pathway coverage from separate kinase inhibitors.

Co-administering ibrutinib and abexinostat targets solid tumors through synergistic kinase and histone deacetylase inhibition.

Azalactam compounds inhibit HPK1 kinase to restore T-cell responses, addressing suppressed immune signaling in current cancer treatments.

E-selectin antagonists mobilize marrow infiltrating lymphocytes into peripheral blood, bypassing time-consuming ex vivo expansion processes.

Morpholino antisense oligomers induce exon-skipping of the IL-17RC pre-mRNA transcript to modulate inflammatory signaling pathways.

Water-soluble CAP7.1 esters bypass multidrug resistance by inhibiting MDR-1 transport proteins, restoring etoposide efficacy in metastatic tumours.

Microwave-synthesized glucosidic astaxanthin reduces radiation-induced oxidative stress without heavy shielding.

Succinate dehydrogenase inhibitors reprogram adult heart metabolism to promote cardiomyocyte proliferation and structural recovery.

Exosome encapsulation directs STING agonists to immune cells, reducing systemic inflammation while enhancing anti-tumor efficacy.

ATM inhibitors reduce viral load and inhibit cell arrest to prevent severe disease progression in COVID-19 treatment.

NTM048 strain exopolysaccharides boost IgA levels, addressing insufficient intestinal immunity from existing lactic acid bacteria.

Protamine sulfate complexes with anionic antisense oligonucleotides to overcome the intact urothelial barrier and improve therapeutic efficacy.

Modified bradykinin analogues reduce nonspecific binding and rapid clearance to improve diagnostic visualization quality.

Aminopyrimidine heterocyclic compound acts as a potent adenosine A2A receptor antagonist.

Polycyclic compounds with specific pyran capping groups improve therapeutic efficacy against resistant hepatitis C genotypes while reducing hepatotoxicity.